Overview of Planned and Ongoing Clinical Studies of Vaccines for COVID-19

Home , BCG vaccine, Tuberculosis vaccines, Vaccine trial

Version of 16.10.2020

Overview of planned and ongoing clinical studies of vaccines for COVID-19

Table of contents

RNA vaccines ...... 3 mRNA-1273, Moderna ...... 3 BNT162, BioNTech ...... 4 CVnCoV, CureVac ...... 6 LUNAR-COV19, Arcturus Therapeutics and Duke-NUS ...... 6 RNA vaccine, Imperial College London ...... 7 People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech...... 7

DNA vaccines ...... 8 INO-4800, Inovio ...... 8 AG0301-COVID19, Osaka University/AnGes/Takara Bio ...... 8 AG0302-COVID19, AnGes...... 8 DNA plasmid vaccine, Cadila Healthcare Limited ...... 9 GX-19, Genexine ...... 9

Non-replicating viral vector ...... 10 AZD1222, ChAdOx1 nCoV-19, Oxford and Astra-Zeneca ...... 10 Ad5-nCoV, CanSino ...... 12 Ad26.COV2-S, JnJ ...... 14 Gam-COVID-Vac Lyo, Gamaleya ...... 15 Grad-CoV2, ReiThera/LEUKOCARE/ Univercells ...... 17 Ad5-nCoV ...... 18

Replicating viral vector ...... 19 TMV-083, Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp & Dohme...... 19 V591-001, Themis/Merck Sharp & Dohme ...... 19

Inactivated virus ...... 20 Coronavac, Sinovac ...... 20 Wuhan Institute of Biological Products, Sinopharm ...... 21 Beijing Institute of Biological Products, Sinopharm ...... 22 Chinese Academy of Medical Sciences ...... 23 QazCovid-in® - COVID-19 inactivated vaccine ...... 24 BBV152, Bharat Biotech ...... 24 Inactivated vaccine, Jiangsu ...... 25

Protein subunit ...... 26 NVX-CoV2373, Novavax ...... 26 Adjuvanted recombinant protein (RBDDimer), Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd...... 27 KBP-COVID-19, Kentucky Bioprocessing, Inc ...... 28 S protein ...... 28 Native like Trimeric subunit Spike Protein vaccine, Clover/GSK/Dynavax ...... 28 COVAX19, Recombinant spike protein with Advax™ adjuvant, Vaxine Pty Ltd/Medytox ...... 29

Version of 16.10.2020

Molecular clamp stabilized Spike protein with MF59 adjuvant, University of Queensland/CLS/Seqirus ...... 29 MVC-COV1901, Medigen Vaccine Biologics Corp...... 29 Protein subunit, Instituto Finlay de Vacunas, Cuba ...... 29 EpiVacCorona, Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" ...... 30 AdimrSC-2f, Adimmune ...... 30

Virus Like Particles ...... 31 RBD-HBsAg VLP ...... 31 Plant derived VLP, Medicago Inc./Université Laval ...... 31

Other vaccine studies, not yet recruiting ...... 32

Other vaccines ...... 33 BCG vaccine ...... 33 Measles-Mumps-Rubella Vaccine ...... 36 Inactivated mycobacterium vaccine ...... 36

Version of 16.10.2020 RNA vaccines Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website mRNA-1273, Moderna NCT04283461 United States, Phase 1 open label dose ranging Relevant safety outcomes; Active, not recruiting High Washington study of the safety and 12 months follow-up Sponsor: National Phase 1 immunogenicity of 2019 nCoV Estimated primary institute of Allergy and vaccine (mRNA1273) in healthy adults completion: Infectious diseases; November 2021 N=120, several doses are being Moderna Therapeutics; tested: 10 mcg, 25 mcg, 50 mcg, 100 Lonza mcg, 250 mcg mRNA-1273 NCT04405076 United states (multiple Phase 2a, randomized, observer- 1. Solicited local and systemic Active, not recruiting High sites) blind, placebo controlled, dose- adverse reactions [Time Frame: Sponsor: Phase 2 confirmation study to assess the 7 days post-vacc] Estimated Primary ModernaTX, Inc. safety, reactogenicity, and 2. Unsolicited adverse events [ Completion Date: March NIAID immunogenicity of 2 dose levels of Time Frame: 28 days post-vacc] 2021 Lonza mRNA-1273 SARS-COV-2 vaccine in 3. Medically-attended adverse adults 18 years of age or older. events [Time Frame: Month 0 through Month 13] N=600 randomized to 50 mcg mRNA- 4. Serious adverse events 1273 or 100 mcg mRNA-1273. [Time Frame: Month 0 through Each participant will receive two Month 13] shots 5. Change in the measure of The randomisation is stratified by clinical safety laboratory values age. 300 individuals 18-54 years and in Cohort 2 from baseline 300 individuals 55+ years [Time Frame: Through 1 month after last vacc] 6. Number and percentage of participants with abnormalities in blood pressure, temp, HR or respiratory rate [Time Frame: Through 1 year after last vacc] 7. Number and percentage of participants with abnormalities in physical examinations [Time Frame: Through 1 year after last vaccination] 8. Evaluate immunogenicity of mRNA-1273 by titer of SARS- CoV-2-specific binding antibody (bAb) measured by enzyme-linked immunosorbent assay (ELISA) [Time Frame: Through 1 year after the final dose]

Version of 16.10.2020 mRNA-1273 NCT04470427 Multicentre study in US A Phase 3, Randomized, Stratified, Number of Participants with a Recruiting High Observer-Blind, Placebo-Controlled First Occurrence of COVID-19 Sponsor: Phase 3 Study to Evaluate the Efficacy, Safety, Starting 14 Days after Second Estimated Primary Moderna and Immunogenicity of mRNA-1273 Dose of mRNA-1273 [ Time Completion Date: October SARS-CoV-2 Vaccine in Adults Aged Frame: Day 29 (second dose) 27, 2022 Collaborators: 18 Years and Older up to Day 759 (2 years after Biomedical Advanced second dose) ] Research and N=30,000 Number of Participants with Development Authority Participants will receive 1 Adverse Events (AEs) or National Institute of intramuscular (IM) injection of 100 Medically Attended AEs Allergy and Infectious microgram (ug) mRNA-1273 or (MAAEs) Leading to Diseases (NIAID) placebo on Day 1 and on Day 29. Withdrawal [ Time Frame: Up to Day 759 (2 years after second dose) ] Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) [ Time Frame: Up to Day 8 (7 days after first dose) and up to Day 36 (7 days after second dose) ] Number of Participants with Unsolicited AEs [ Time Frame: Up to Day 57 (28 days after each dose) ]

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website BNT162, BioNTech EudraCT Number: Germany Phase I/II, multi-site, non- 1. Solicited local reactions at Recruiting; High 2020-001038-36 randomized, open-label trial the injection site (pain, Estimated Primary BioNTech mRNA vaccine investigating the safety and tenderness, erythema/redness, Completion Date: NCT04380701 immunogenicity of four prophylactic induration/swelling) recorded August 2020 BNT162a1 SARS-CoV-2 RNA vaccines against up to 7±1 days after each BNT162b1 U1111-1249-4220 COVID-2019 using different dosing immunization. BNT162b2 regimens in healthy adults. BNT162c2 BNT162-01 2. Solicited systemic reactions N=200 (nausea, vomiting, diarrhea,

Phase 1/2 headache, fatigue, myalgia, Pharmaceuticals GmbH The trial has two parts. arthralgia, chills, loss of + appetite, malaise, and fever) Pfizer Inc. Part A: a dose-finding part with four dose cohorts for each vaccine and recorded up to 7±1 days after one pre-defined and one optional each immunization. dose level for a de-escalation approach. 3. The proportion of subjects - BNT162a1 (i.m., escalating dose with at least 1 unsolicited levels) treatment emergent adverse event (TEAE): [ Time Frame: 21 4

Version of 16.10.2020

- BNT162b1 (i.m., escalating dose days following dose levels) administration ] - BNT162b2 (i.m., escalating dose levels) 4. The proportion of subjects - BNT162c2 (i.m., single dose) with at least 1 unsolicited treatment emergent adverse Part B: dedicated to recruit expansion event (TEAE): [ Time Frame: 28 cohorts with dose levels which are days following dose selected from data generated in Part administration ] A. Sponsors: Jiangsu ChiCTR2000034825 China, Jiangsu A Phase I clinical trial of novel Adverse events up to 21 post Study duration: From High Provincial Center for coronavirus pneumonia (COVID-19) vaccination 2020-07-20 to 2020-12-31 Disease Prevention and Phase 1/2 mRNA Vaccine (BNT162b1) in China Control. BioNTech RNA Pharmaceuticals GmbH. Shanghai Fosun Pharmaceutical Development, Inc. BNT162b3 NCT04537949 Germany A Multi-site, Phase I/II, 2-Part, Dose- Safety measures Recruiting; High BioNTech RNA Escalation Trial Investigating the Estimated Primary Pharmaceuticals GmbH Phase 1/2 Safety and Immunogenicity of a Completion: September Prophylactic SARS-CoV-2 RNA Vaccine 2021 (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults BNT162b NCT04523571 Jiangsu, China Safety and Immunogenicity of SARS- Safety measures Recruiting; High CoV-2 mRNA Vaccine (BNT162b1) in Estimated Primary Sponsor: Biontech Phase 1 Chinese Healthy Subjects: A Phase I, Completion: September Collaborator: Shanghai Randomized, Placebo-controlled, 2020 Fosun Pharmaceutical Observer-blind Study Development Ca, Ltd N=144 BNT162 NCT04368728 Argentina, Brazil, South Phase 1/2/3 observer-blinded, Phase 1: Active, not recruiting High Africa, Turkey, United placebo-controlled, randomized Percentage of participants BioNTech mRNA vaccine Phase 1/2/3 States dose-finding trial to Describe the reporting: Estimated primary Safety, Tolerability, Immunogenicity, - Local reactions Completion Date: June 28, BNT162b1 and Potential Efficacy of Covid-19 - Systemic events 2021 BNT162b2 RNA Vaccine Candidates Against - (Serious) Adverse COVID-19 in Healthy Adults events Sponsor: Biontech SE Collaborator: Pfizer N = 29481 healthy adults in age Percentage of sentinel cohort groups: 18-55, 65-85 and 18-85. participants with grading shifts and abnormal hematology and Randomized to receive single dose of laboratory values low-, medium- or high-dose or two doses of low-, medium- or high- Phase 2/3 study: safety dose of BNT162b1, BNT162b2, or measures up to 6 months post placebo injection (21 arms) vaccination 5

Version of 16.10.2020

Phase 2/3 study: confirmed covid-19 from 7 days after the last dose of study intervention to the end of the study, up to 2 years

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website CVnCoV, CureVac NCT04449276 Germany A Phase 1, Partially Blind, Placebo- Safety Recruiting; High controlled, Dose-escalation, First-in- Estimated primary Sponsor: Curevac, CEPI Phase 1 human, Clinical Trial to Evaluate the completion: August 2021 Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults. N=168 CVnCoV , Curevac NCT04515147 Not stated yet A Phase 2a, Partially Observer-blind, Safety, antibodies, neutralising Not yet recruiting; High Multicenter, Controlled, Dose- antibodies Estimated Primary Phase 2 confirmation Clinical Trial to Evaluate Completion: November 9, the Safety, Reactogenicity and 2021 Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age N=691 randomised to 6 microgram, 8 microgram, 4 μg double dose, hepatitis A, pneumococ

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website LUNAR-COV19, Arcturus NCT04480957 Singapore A Phase 1/2 Randomised, Double Incidence, severity and dose- Recruiting; High Therapeutics and Duke- Blinded, Placebo Controlled, relationship of AEs [ Time NUS Phase 1/2 Ascending Dose Study to Assess the Frame: 56 days ] Estimated primary Safety, Tolerability, and completion: (ARCT-021) Immunogenicity of ARCT-021 in December 2020 Healthy Adult Subjects Sponsor: Arcturus N=92 randomised to 3 different Therapeutics, Inc doses and 2 different dosing regimen

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website

Version of 16.10.2020

RNA vaccine, Imperial https://www.imperia UK A first-in-human clinical trial to assess Adverse events Planned to start mid June High College London l.ac.uk/covid-19- the safety and immunogenicity of a and last for 2 months vaccine-trial/ self-amplifying ribonucleic acid Neutralising antibodies Interim results available LNP-nCoVsaRNA (saRNA) vaccine encoding the S end of August ISRCTN17072692 glycoprotein of SARS-CoV-2, the Vaccine induced serum IgG causative agent of COVID-19 binding antibodies Phase 1

3 components of the trial: Open-label, non-randomised dose escalation: 15 participants age 18-45 will be in the dose-escalation component.

Randomised dose evaluation: 105 individuals aged 18-45 will be enrolled through a single centre. Participants and laboratory staff will be blind to allocation. Participants will be allocated in a 1:1:1 ratio to the three different doses based on block randomisation. They will be followed up for 52 weeks in total.

Non-randomised expanded safety evaluation: At least 200 individuals aged 18-75 will receive the highest dose (1 µg) enrolled through multiple centres.

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website People's Liberation Army ChiCTR2000034112 Zhejiang and Guangxi A Phase I clinical trial to evaluate the IgG antibody, Neutralizing From 2020-06-25 To 2021- High (PLA) Academy of Zhuang Autonomous safety, tolerance and preliminary antibody, cellular immunity 12-31 Military Sciences/Walvax Phase 1 Region, China immunogenicity of different doses of Biotech. a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and above

N=168

Version of 16.10.2020 DNA vaccines Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website INO-4800, Inovio NCT04336410 United States, Kentucky, Phase 1 Open-label Study to Evaluate Safety and efficacy Active, not recruiting; High Device: CELLECTRA® 2000 Missouri and the Safety, Tolerability and Time frame week: 52 Estimated Primary Phase 1 Pennsylvania Immunogenicity of INO-4800 for a Completion: Sponsor: Inovio Novel Coronavirus (COVID-19) in July 2021 Pharmaceuticals Healthy Volunteers

N=120 Two different doses will be tested INO-4800 NCT04447781 Not stated yet A Phase I/IIa, Dose-Ranging Trial to Safety and efficacy Recruiting; High Evaluate Safety, Tolerability and Time frame week: 52 Sponsor: Phase 1/2 Immunogenicity of INO-4800 Estimated primary International Vaccine Insti completion: February 22, tute N=160 participants 2022

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website AG0301-COVID19, Osaka JapicCTI-205328 Osaka City University Phase 1 Incidence of Treatment- Acctive, not recruiting High University/AnGes/Takara Hospital, Japan A Non-randomized, Open-label, Non- Emergent Adverse Events Estimated primary Bio https://www.clinicalt controlled Phase I/II Study to Assess [Safety and Tolerability]) [ Time completion date: rials.jp/cti- Safety and Immunogenicity of Two Frame: Week 1 through Week September 26, 2020 DNA plasmid vaccie + user/trial/ShowDirec Doses of Intramuscular AG0301- 9 ] adjuvant t.jsp?clinicalTrialId=3 COVID19 (1mg/2mg) in Healthy Duration: 25.6.2020- 0761 Adults 31.7.2021 Sponsor: AnGes, Inc Immunogenicity [ Time Frame: NCT04463472 N=30 Weeks 3, 5, 7, 9 ] Collaborator: Japan Agency for Medical Phase 1 Research and Development AG0302-COVID19, AnGes NCT04527081 Japan Randomized, Open-label, Non- Incidence of Treatment- Recruiting; High controlled Phase I/II Study to Assess Emergent Adverse Events Estimated Primary DNA plasmid vaccie + Phase 1/2 Safety and Immunogenicity of Twice [Safety and Tolerability] [ Time Completion: adjuvant or Three Times Dosing of Frame: Week 1 through Week November 26, 2021 Intramuscular AG0302-COVID19 9 ] Sponsor: AnGes (2mg) in Healthy Adults N=30 Immunogenicity [ Time Frame: Weeks 3, 5, 7, 9 ]

Version of 16.10.2020

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website DNA plasmid vaccine, CTRI/2020/07/02635 India A prospective, randomized, adaptive, Phase I: To evaluate the safety Recruiting; High Cadila Healthcare 2 phase I/II clinical study to evaluate of Novel Corona Virus-2019- Estimated Primary Limited the safety and immunogenicity of nCov Vaccine Candidate of M/s Completion: Phase 1/2 Novel Corona Virus -2019-nCov Cadila Healthcare Limited by July 13, 2021 vaccine candidate intradermal route in healthy N=1048 subjects. (day 0 and day 84)

3 doses Phase II: To evaluate the immunogenicity of Novel Corona Virus-2019-nCov Vaccine Candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects compared to placebo. (day 0 and day 224)

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website GX-19, Genexine NCT04445389 Republic of Korea A Phase 1/2a, Multi-center, Incidence of solicited adverse Recruiting; High Randomized, Double-blind, Placebo- events [ Time Frame: Through Estimated Primary Sponsor: Genexine, Inc. Phase 1/2 controlled Study to Investigate the 1 year post vaccination ] Completion: Safety, Tolerability, and March 17, 2021 Immunogenicity of GX-19 Incidence of unsolicited N=210 adverse events [ Time Frame: Through 1 year post vaccination ]

Incidence of serious adverse events [ Time Frame: Through 1 year post vaccination ]

Version of 16.10.2020 Non-replicating viral vector Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website AZD1222, ChAdOx1 NCT04324606 UK A Phase I/II Study Number of virologically Active, not recruiting High nCoV-19, Oxford and Single-blinded, randomised, placebo confirmed (PCR positive) Astra-Zeneca 2020-001072-15 controlled, multi-centre study symptomatic cases of COVID- Estimated primary N: 510 19 Completion: COV001 Healthy volunteers aged 18-55 October 2021 Based on adenovirus Number of study participants has Occurrence of serious adverse vaccine vector with SARS- Phase 1/2 been increased to 1112. events (SAEs) throughout the CoV-2 spike protein. study duration

AZD1222, ChAdOx1 NCT04444674 Multicentre study in An Adaptive Phase I/II Randomized Incidence of adverse events in Recruiting; High nCoV-19 South Africa Placebo-controlled double-blinded HIV-negative and HIV-positive PACTR202006922165 Trial to Determine Safety, adults [ Time Frame: Up to 12 Estimated Primary 132 Immunogenicity and Efficacy of Non- months post enrollment ] Completion: October 2020 replicating ChAdOx1 SARS-CoV-2 Phase 1/2 Vaccine in South African Adults Living Determine if there is a Without HIV; and Safety and reduction of severe and non- Immunogenicity in Adults Living With severe COVID-19 disease in HIV HIV-negative adults who receive candidate vaccine N=2000 ChAdOx1 nCoV-19 compared to placebo recipients (efficacy) [ Time Frame: Up to 12 months post enrollment ]

Assess cellular and humoral Immunogenicity of ChAdOx1 nCoV-19 in people living with HIV [ Time Frame: Up to 12 months post enrollment ] AZD1222, ChAdOx1 NCT04568031 Japan A Phase I/II Randomized, Double- Proportion of participants who Recruiting; High nCoV-19 blind, Placebo-controlled Multicentre have a post treatment sero Estimated Primary Phase 1/2 Study in Participants Aged 18 Years or response [ Time Frame: Day 29 Completion: September 6, Older to Determine the Safety and or Day 57 ] 2021 Immunogenicity of AZD1222, a Non- replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

N=12 AZD1222, ChAdOx1 NCT04400838 UK Phase II/III study to determine the Efficacy: Number of Recruiting; High nCoV-19 efficacy, safety and immunogenicity virologically confirmed (PCR 2020-001228-32 of the ChAdOx1 nCoV-19 in healthy positive) symptomatic cases of Estimated primary UK volunteers. COVID-19 [ Time Frame: 6 completion: August 2021 Phase 2/3 A randomised, single blinded trial. months ]

Version of 16.10.2020

N= 10,260 adults and children Safety: Occurrence of serious Phase 2 study: from 5 years of age adverse events (SAEs) Phase III study: from 18 years throughout the study duration. [ Time Frame: 6 months ] Comparator: Menveo or Nimenrix (meningococcal vaccines) AZD1222, ChAdOx1 ISRCTN89951424 Brazil A phase III randomized controlled Virologically confirmed (PCR Ongoing High nCoV-19 trial to determine safety, efficacy, and positive) symptomatic cases of Study duration May 2020 Phase 3 immunogenicity of the non- COVID-19 over the course of 12 to July 2021 replicating ChAdOx1 nCoV-19 vaccine months. Single-blind All participants will be invited to follow-up visits at day 28, Participants will be randomised (1:1 90, 182 and 364 and using block randomisation) to receive participants will be asked to either ChAdOx1 nCoV-19 or contact the study team if they MenACWY (licensed control vaccine). develop symptoms suggestive Participants will also be advised to of COVID-19 at any point take paracetamol for 24 hours after during the trial. Symptomatic vaccination if there are no participants will be asked to contraindications to doing so. present for a visit to test for SARS-CoV-2 PCR.

N=2000 AZD1222, ChAdOx1 NCT04516746 USA A Phase III Randomized, Double-blind, Efficacy: A binary response, Not yet recruiting; High nCoV-19 Placebo-controlled Multicenter Study whereby a participant is Estimated Primary Phase 3 in Adults to Determine the Safety, defined as a COVID-19 case if Completion: December 2, Efficacy, and Immunogenicity of their first case of SARS-CoV-2 2020 AZD1222, a Non-replicating ChAdOx1 RT-PCR-positive symptomatic Vector Vaccine, for the Prevention of illness occurs ≥ 15 days post COVID-19 second dose of study N=30.000 + 18 years intervention. Otherwise, a participant is not defined as a COVID-19 case.(time frame 1 year)

Safety: Incidence of adverse events. (Time Frame: 28 days post each dose of study Intervention) Incidence of serious adverse events, medically attended adverse events, and adverse events of special interest (from Day 1 post-treatment through Day 730) Incidence of local and systemic solicited adverse events. 11

Version of 16.10.2020

(Time Frame: 7 days post each dose of study intervention. )

AZD1222, ChAdOx1 NCT04540393 Moscow, Russia A Phase III Open-label Study in Adults Incidence of SAEs following the Not yet recruiting; High nCoV-19 to Determine the Safety and first vaccination and Estimated Primary Phase 3 Immunogenicity of AZD1222, a Non- throughout the study duration Completion Date: replicating ChAdOx1 Vector Vaccine, (Day 180) [Safety and March 5, 2021 for the Prevention of COVID-19. Tolerability]. [ Time Frame: 180 N=100 days ] AZD1222, ChAdOx1 CTRI/2020/08/02717 India This is a Phase 2/3, observer-blind, 1. Occurrence of causally Recruiting; High nCoV-19 0 randomised, controlled study in related SAEs throughout the healthy adults in India, for study duration following Estimated completion Phase 2/3 comparison of the safety of vaccination date: June 2020 COVISHIELD with Oxford/AZ-ChAdOx1 2. Ratio of GMTs nCoV-19 and Placebo, and of anti-S IgG antibodies immunogenicity with Oxford/AZ- ChAdOx1 nCoV-19 in prevention of SARS CoV-2 infection. A total of 1600 eligible participants of more than or equal to 18 years of age will be enrolled the study. Of these 400 participants will be part of immunogenicity cohort and will be randomly assigned in a 3:1 ratio to receive either COVISHIELD or Oxford/AZ-ChAdOx1 nCoV-19, respectively. The remaining 1200 participants from safety cohort will be randomly assigned in a 3:1 ratio to receive either COVISHIELD or Placebo, respectively. 2 doses (day 1 and 29)

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Ad5-nCoV, CanSino ChiCTR2000030906 Hubei, China A single-center, open and dose- Adverse reactions 7 days post Active, not recruiting High NCT04313127 escalation phase I clinical trial for injection Recombinant Novel recombinant novel coronavirus Estimated primary Coronavirus Vaccine, Phase 1 (2019-COV) vaccine (adenoviral completion: Adenovirus Type 5 Vector vector) Dec 30 2020 N=108 Healthy adults treated with 3 Sponsor: CanSino different doses Biologics Inc.

Version of 16.10.2020

Ad5-nCoV NCT04568811 China, Hubei Single-center, Open-label Phase I Occurrence of adverse Active, not recruiting; High Jiangsu Province Centers Clinical Trial of Booster Vaccination of reactions within 14 days after Estimated Primary for Disease Control and Phase 1 Adenovirus Type-5 Vectored COVID- booster vaccination [ Time Completion Date: October Prevention 19 Vaccine in Healthy Adults Aged 18- Frame: 0-14 days post- 25, 2020 60 Years vaccination] N=89 Ad5-nCoV NCT04341389 China, Hubei A Randomized, Double-blind, Occurrence of adverse Active, not recruiting; High ChiCTR2000031781 Placebo-controlled Phase II Clinical reactions [ Time Frame: 0-14 Institute of Trial to Evaluate the Safety and days post vaccination ] Estimated Primary Biotechnology, Phase 2 Immunogenicity of the Recombinant Anti SARS-CoV-2 S antibody Completion: Academy of Military Novel Coronavirus Vaccine response(ELISA) [ Time Frame: January 31, 2021 Medical Sciences, PLA of (Adenovirus Vector) in Healthy Adults 28 days post vaccination ] China Aged Above 18 Years Neutralizing antibody response N=500 healthy individuals to SARS-CoV-2 [ Time Frame: CanSino Biologics Inc. randomised to 28 days post vaccination ] 1×10^11vp of Ad5-nCoV 5×10^10vp of Ad5-nCoV Placebo Ad5-nCoV NCT04398147 Canada Phase I /II adaptive clinical trial to Solicited AE in all groups [ Time Not yet recruiting; High evaluate the safety, tolerability and Frame: 0-6 days after each Sponsor and Phase 1/2 the Immunogenicity of Ad5-nCoV in vaccination ] Estimated Primary collaborators: healthy adults from 18 to <55 and 65 Completion: December CanSino Biologics Inc. to <85 years of age with the Unsolicited AE in all groups [ 2021 randomized, observer-blind, dose- Time Frame: 0-28 days after Beijing institute of escalation design. each vaccination ] biotechnology N=96 will be included in the dose- Serious adverse events (SAE) in escalating study (phase I) Canadian Center for all groups [ Time Frame: 6 5E10vp and 10E10vp, Vaccinology months after the final Of each of the 2 doses, single dose vaccination ] and 2 doses will be tested.

N=600 will be included in the phase 2 trial Ad5-nCoV NCT04566770 China, Jiangsu A Randomized, Double-blind, Placebo Safety and immunogenicity Recruiting; High CanSino Biologics Inc. -Controlled Phase IIb Clinical Trial to Estimated Primary Beijing Institute of Phase 2 Evaluate the Safety and Completion Date : August Biotechnology Immunogenicity of Ad5-nCoV in 21, 2021 Jiangsu Province Centers Person 6 Years of Age and Older and for Disease Control and Those Who Have Previously Been Prevention Vaccinated With Ad5-EBOV N=481

Version of 16.10.2020

Ad5-nCoV NCT04526990 Pakistan A Global Multicenter, Randomized, Incidence of COVID-19 cases [ Not yet recruiting; High Double-blind, Placebo -Controlled, Time Frame: day 28 to 12 Estimated Primary Sponsors: Phase 3 Adaptive Designed Phase Ⅲ Clinical months post vaccination ] Completion: December 30, CanSino Biologics Inc. Trial to Evaluate the Efficacy, Safety 2021 Beijing Institute of and Immunogenicity of Ad5-nCoV in Incidence of SAE [ Time Frame: Biotechnology Adults 18 Years of Age and Older Within 12 months ] N=40.000 Ad5-nCoV NCT04540419 Russia Multicenter, Randomized, Double Superiority of the vaccine Ad5- Recruiting; High Blind, Placebo Controlled Parallel nCoV to placebo by the level of NPO Petrovax Phase 3 Group Study Evaluating Efficacy, seroconversion [ Time Frame: Estimated Primary CanSino Biologics Inc. Reactogenicity and Safety of Day 28 after vaccination ] Completion: November 30, Recombinant Vaccine Ad5-nCoV Assessed as the proportion of 2020 Against Novel Coronavirus Infection subjects with four-fold and in Adult Volunteers higher increment of anti- receptor-binding domain N= 500, 18-85 years randomized 2:1 antibodies [receptor-binding to single dose vaccine or placebo domain, RBD] of S-protein SARS-CoV-2).

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Ad26.COV2-S, JnJ NCT04436276 US and Belgium A Randomized, Double-blind, Safety parameters Recruiting; High Placebo-controlled Phase 1/2a Study Estimated Primary (JNJ-78436735) Phase 1/2 to Evaluate the Safety, Completion: September Sponsor: Reactogenicity, and Immunogenicity 15, 2021 Janssen Vaccines & of Ad26COVS1 in Adults Aged 18 to Prevention B.V., Johnson 55 Years Inclusive and Adults Aged 65 & Johnson Years and Older

N=1045 Cohort 1a and 1b and 3: 2 dose levels, 1 or 2 doses with 56 days interval of Ad26.COV2.S or placebo

Cohort 2a: High dose or matching placebo at day 1 followed by booster at 6, 12 and 24 months.

Cohort 2b: 2 low doses or matching placebo at day 1 and 57 followed by booster at 8, 14 and 26 months after completion of primary regimen

Version of 16.10.2020

Ad26.COV2-S, JnJ NCT04509947 Japan A Randomized, Double-blind, Safety parameters Recruiting; High Placebo-controlled Phase 1 Study to Estimated Primary (JNJ-78436735) Phase 1 Evaluate the Safety, Reactogenicity, Completion: January 8, Sponsor: and Immunogenicity of Ad26.COV2.S 2021 Janssen Vaccines & in Adults Prevention B.V., Johnson N=250 randomised to low dose, high & Johnson dose or placebo.

Two injections at day 1 and 57 Ad26.COV2-S, JnJ NCT04505722 US, Argentina, Brazil, A Randomized, Double-blind, Number of Participants with Recruiting; High Chile, Columbia, Mexico, Placebo-controlled Phase 3 Study to First Occurrence of Molecularly Estimated Primary (JNJ-78436735) Phase 3 Peru, Philippines, South Assess the Efficacy and Safety of Confirmed Moderate to Completion: March 10, Sponsor: Africa, Ukraine Ad26.COV2.S for the Prevention of Severe/Critical Coronavirus 2023 Janssen Vaccines & SARS-CoV-2-mediated COVID-19 in Disease (COVID-19) with Prevention B.V., Johnson Adults Aged 18 Years and Older Seronegative Status [ Time & Johnson Frame: Up to 2.1 years ] N=60000 randomised to Ad26.COV2.S Moderate defined as one sign 1^10*11 virus particles (vp) as single and one symptom from a list of dose vaccine on Day 1 or placebo. signs, such as respiratory rate >90 and symptoms such as shortness of breath or cough or 2 symptoms from a list of symptoms or Severe COVID-19 defined in FDA guidance.

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Gam-COVID-Vac Lyo, NCT04437875 Moscow, Russian An open, prospective, two-stage, The changing of antibody levels Completed; High Gamaleya Federation non-randomized, first-phase study against the SARS-CoV-2 Phase 1/2 involving healthy volunteers glycoprotein S at 42 days [ Actual Primary Completion Adenovector virus Time Frame: at days 0, 14, 21, Date: August 3, 2020 N=38 28, 42 ] Gamaleya Research Actual Study Completion Institute of Epidemiology 3 arms: Number of Participants With Date: August 10, 2020 and Microbiology, Health Adverse Events [ Time Frame: Ministry of the Russian rAd26 Component, through the whole study, an Federation 1 vaccination Component 1 consists average of 180 days ] of a recombinant adenovirus vector based on the human adenovirus type

rAd5 Component, 1 vaccination Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene.

Prime-boost: Day 1 rAd26, 15

Version of 16.10.2020

Day 21 rAd5 Gam-COVID-Vac NCT04436471 Moscow, Russian An open, prospective, two-stage, Changing ofantibody levels Completed; High Federation non-randomized, first-phase study against the SARS-CoV-2 rAd26 Component, 1 Phase 1/2 involving healthy volunteers glycoprotein S in 42 days [ Actual Primary Completion vaccination (recombinant Time Frame: at days 0,14, 21, Date: August 3, 2020 adenovirus vector) N=38 28, 42 ] Number of Participants With Actual Study Completion rAd5 Component, 1 3 arms: Adverse Events [ Time Frame: Date: August 10, 2020 vaccination (a vector through the whole study, an based on the human rAd26 Component, average of 180 days ] adenovirus type 5) 1 vaccination Component 1 consists of a recombinant adenovirus vector Gamaleya Research based on the human adenovirus type Institute of Epidemiology 26 and Microbiology, Health Ministry of the Russian rAd5 Component, Federation 1 vaccination Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene.

Prime-boost: Day 1 rAd26, Day 21 rAd5 Gam-COVID-Vac NCT04587219 Russian An Open Study of the Safety, Changing of antibody levels Not yet recruiting; High Tolerability and Immunogenicity of against the SARS-CoV-2 Estimated Primary Sponsor: Gamaleya Phase 2 the "Gam-COVID-Vac"Vaccine Against glycoprotein S in 42 days [ Completion Date : Research Institute of COVID-19 (Solution for Intramuscular Time Frame: at days 0, 21, 28, Decem Epidemiology and Injection) With the Participation of 42 ] ber 15, 2020 Microbiology, Health Volunteers in the Age Group Over 60 Ministry of the Russian Years Number of Participants With Federation Single arm Adverse Events [ Time Frame: N=110 through the whole study, an average of 180 days ] Gam-COVID-Vac NCT04530396 Russia Randomized Double-blind Placebo- Percentage of trial subjects Recruiting, Estimated High controlled Multi-center Clinical Trial with coronavirus disease 2019 Primary Completion: May Gamaleya Research Phase 3 in Parallel Assignment of Efficacy, (COVID-19) developed within 6 1, 2021 Institute of Epidemiology Safety, and Immunogenicity of Gam- months after the first dose [ and Microbiology, Health COVID-Vac Combined Vector Vaccine Time Frame: through the Ministry of the Russian in SARS-СoV-2 Infection Prophylactic whole study, an average of 180 Federation Treatment days ]

Government of the city of N=40.000 randomised 3:1 to Gam- Moscow COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost CRO: Crocus Medical BV immunization in days 1 (component I rAd26-S) and 21(component II rAd5- S) or placebo 16

Version of 16.10.2020

Gam-COVID-Vac NCT04564716 Belarus Сlinical Trial of Efficacy, Safety and percentage of trial subjects Recruiting; High Gamaleya Research Immunogenicity of Combined Vector with coronavirus disease 2019 Institute of Epidemiology Phase 3 Vaccine Gam-COVID-Vac in SARS-СoV- (COVID-19) developed within 6 Estimated Primary and Microbiology, Health 2 Infection Prophylactic Treatment in months after the first dose [ Completion: March 28, Ministry of the Russian Republic of Belarus Time Frame: through the 2021 Federation N=100 randomised 3:1 to Gam- whole study, an average of 180 COVID-Vac combined vector vaccine, days ] RDIF (Russian Direct 0,5ml/dose+0,5 ml/dose prime-boost Investment Fund) immunization in days 1 (component I rAd26-S) and 21(component II rAd5- CRO: iPharma S) or placebo

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Grad-CoV2, 2020-002835-31 Italy A phase 1 dose escalation study to Safety measures Recruiting; High ReiThera/LEUKOCARE/ evaluate the safety and Univercells https://www.reither immunogenicity of GRAd-CoV2. The Adult enrolment is a.com/2020/08/03/c study involves 90 healthy volunteers expected to end in the Replication defective ovid-19-aifa- in two sequential cohorts (adult second week of Simian Adenovirus autorizza-la- cohort and elderly cohort): September and the first (GRAd) encoding S sperimentazione-di- 18-55 years and 65-85 years. safety and immunogenicity fase-i-del-vaccino- results will be available by reithera-in-italia/ N=90 the second week of There are three treatment arms (with October. NCT04528641 three increasing doses of vaccine), The enrolment of the consisting of 15 participants each, for elderly will end in the first Phase 1 a total of 6 groups. week of November and the first results will arrive by the second week of December. Final safety and immunogenicity data will be available within one year of study approval. Estimated primary completion: July 31, 2021

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website

Version of 16.10.2020

Ad5-nCoV NCT04552366 China, Hubei A Clinical Trial to Evaluate the Safety Safety and immunogenicity Recruiting; High and Immunogenicity of a Muccosal and IM Phase 1 Recombinant Adenovirus 5 Vectored Estimated Primary administration COVID-19 Vaccine (Ad5-nCoV) With Completion: December 31, Two Doses in Healthy Adults Aged 18 2020 Sponsor: Institute of Years and Older. Biotechnology, Academy of Military Medical The safety and immunogenicity of Sciences, PLA of China intramuscular vaccination and mucosal vaccination of two doses of Ad5-nCoV in different administration schedules will be evaluated

N=144

Version of 16.10.2020 Replicating viral vector Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website TMV-083, Institute NCT04497298 Belgium, France A Randomized, Placebo-controlled To assess the safety and Recruiting; High Pasteur/Themis/Univ. of Trial, to Evaluate the Safety and tolerability of the COVID-19 Pittsburg CVR/Merck Phase 1 Immunogenicity of the COVID-19 vaccine following one or two Estimated primary Sharp & Dohme Vaccine, a Measles Vector-based consecutive intramuscular completion: November Vaccine Candidate Against COVID-19 injections in healthy volunteers 2020 Measles-vector based in Healthy Volunteers Consisting of an [ Time Frame: Day 390 ] Unblinded Dose Escalation and a Sponsor: Institut Pasteur Blinded Treatment Phase. Collaborators: Themis Bioscience GmbH N=90. Coalition for Epidemic 2 doses and 2 regimens will be tested. Preparedness Innovations (CEPI)

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website V591-001, Themis/Merck NCT04498247 Belgium, France A Phase 1/Phase 2, Randomized, Adverse events up to 365 days Recruiting; High Sharp & Dohme Double-Blind, Placebo-Controlled, post vaccination Phase 1/2 Dose-Ranging Trial to Evaluate the Estimated primary Measles-vector based Safety, Tolerability and completion: March 16, Immunogenicity of V591 (COVID-19 2022 Sponsor: Merck Sharp & Vaccine) in Healthy Younger and Dohme Corp. Older Participants N=260

Version of 16.10.2020 Inactivated virus Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Coronavac, Sinovac NCT04352608 China, Jiangsu Randomized, double-blinded, and 1.Safety indexes of adverse Active, not recruiting; High placebo controlled phase I/II clinical reactions [ Time Frame: up to Formalin-inactivated and Phase1/2 trial of the SARS-CoV-2 inactivated 28 days after the whole Actual Primary Completion alum-adjuvanted vaccine. schedule vaccination ] Date: July 10, 2020

Inactivated SARS-CoV-2 Healthy adults aged 18-59 Years. 2.Neutralizing-antibody vaccine (Vero Cell) N (estimated) = 744 seroconversion rates for the emergency vaccination Sponsor: Sinovac schedule (0 and 14) [ Time Research & Development Frame: The 14th day after two Co., Ltd doses of vaccination ]

3.Neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28) [ Time Frame: The 28th day after two doses of vaccination ] NCT04383574 China, Hebei Phase 1/2, double-blinded, placebo- Safety index-incidence of Active, not recruiting; High controlled, randomized trial for adverse reactions [Time Frame: Phase 1/2 Prevention of Covid-19 infection. Day 0-28 after each dose Actual Primary Completion vaccination] Date: August 28, 2020 N = 422 (72 in phase 1 and 350 in phase 2), age ≥ 60, healthy, randomized to two doses of low, medium or high dosage or placebo NCT04551547 China, Hebei A Randomized, Double-Blinded, Safety index-incidence of Not yet recruiting; High Placebo-Controlled, Phase Ⅰ/Ⅱ adverse reactions [ Time Phase 1/2 Clinical Trial. Frame: Day 0-28 after each Estimated Study Start 2 dose regimen day 0 and 28. dose vaccination ] Date: September 28, 2020 N=552, 3-17 years old Randomised to low dose Immunogenicity index- Estimated Primary (300SU/0.5ml), medium dose seroconversion rates of Completion: January 2021 (600SU/0.5ml) or placebo neutralizing antibody [ Time Frame: The 28th day after the second dose vaccination ] Coronavac, Sinovac NCT04456595 Brazil Double-Blind, Randomized, Placebo- Incidence of COVID-19 cases Recruiting; High Controlled Phase III Clinical Trial to after two-doses immunization Phase 3 Evaluate Efficacy and Safety in schedule [ Time Frame: Two Estimated primary Sponsor: Sinovac Healthcare Professionals of the weeks after second dose up to completion date: Research and Adsorbed COVID-19 (Inactivated) one year after first dose ] September 2021 Development Co., Ltd. Vaccine Manufactured by Sinovac Number of virologically- confirmed symptomatic N= 8870 20

Version of 16.10.2020

Collaborator. Butantan COVID-19 two weeks after Institute second dose of vaccine

Frequency of adverse events [ Time Frame: Seven days after each immunization ] Frequency of adverse reaction in the seven days following each immunization per age group Sinovac NCT04508075 Indonesia A Phase III, Observer-blind, Incidence of laboratory- Recruiting; High Randomized, Placebo-controlled confirmed COVID-19 after the Estimated Primary Sponsor: PT Bio Farma, https://www.ina- Study of the Efficacy, Safety and second dose [ Time Frame: 14 Completion; January 2021 Collaborators: Faculty of registry.org/index.ph Immunogenicity of SARS-CoV-2 days to 6 months after the Medicine Universitas p?act=registry_trial_ Inactivated Vaccine in Healthy Adults second dose ] Padjadjaran. detail&code_trial=16 Aged 18-59 Years in Indonesia. Percentage of laboratory- National Intitute of 202009080721WXF confirmed COVID-19 cases Health Research and M0YX N=1620 randomised to Sinovac Development, Ministry of 669/UN6.KEP/EC/20 vaccine or placeno Health Republic of 20 Indonesia. Sinovac Life Sciences Co., Phase 3 Ltd. Sinovac, NCT04582344 Turkey Randomized, Double-Blind, Placebo- Protection Indexes of Two Recruiting; High Controlled Phase III Clinical Trial For Vaccine Doses For Estimated Primary Sponsor: Health Institutes Phase 3 Evaluation of Efficacy and Safety Symptomatic COVID-19 [ Time Completion Date : of Turkey of SARS-CoV-2 Vaccine (Vero Cell), Frame: 2 weeks after the Februa Inactivated second dose of vaccination ] ry 15, 2021

N=13,000 randomised to vaccine or placebo, to doses with 14 days interval

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Wuhan Institute of ChiCTR2000031809 China, He’nan , Jiaozuo Randomized, double-blind, placebo Incidence of adverse From 2020-04-11 To 2021- High Biological Products, parallel-controlled phase I/II clinical reactions/events 11-10 Sinopharm Phase 1/2 trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells) Inactivated vaccine (Vero cells) Healthy volunteers, from 6 years of Henan Provincial Center age for Disease Control and Multiple doses Prevention Funding:

Version of 16.10.2020

Ministry of Science and Technology, China

Wuhan vaccine ChiCTR2000039000 Marocco Randomized, double-blinded, placebo To evaluate the 4-fold increase From2020-09-02To 2020- parallel-controlled phase III clinical rate, GMT and GMI of anti- 12-31 Sponsor: China National Phase 3 trial to evaluate the Immunogenicity SARS-CoV-2 neutralizing Biotec Group Co.Ltd and safety of the inactivated SARS- antibody 28 days after full CoV-2 Vaccine (Vero cell) in healthy course of immunization population aged 18 years and above

N=600

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Beijing Institute of ChiCTR2000032459 China, He'nan, Shangqiu A phase 1/2 randomized, double- Incidence of adverse From 2020-04-28 To 2021- High Biological Products, blind, placebo parallel-controlled reactions/events 11-28 Sinopharm Phase 1/2 clinical trial to evaluate the safety and immunogenicity of inactivated novel Inactivated vaccine (Vero coronavirus (2019-CoV) vaccine (Vero cells) cells) Sponsor: Henan Provincial Center for Disease N = 2128??? Control and Prevention Healthy volunteers from 3 years of Funding: age Ministry of Science and Multiple doses Technology, China and Sinopharm Beijing Institue of NCT04560881 Argentina Randomized, Double Blind, Placebo Incidence of COVID-19 cases Recruiting; High Biological Products, Parallel-controlled Phase III Clinical after two-doses of vaccination China National Biotec Phase 3 Trial to Evaluate the Efficacy, [ Time Frame: 14 days after the Estimated Primary Group Company Limited Immunogenicity and Safety of the full course of vaccination ] completion: December 1 The Huesped Foundation Inactivated SARS-CoV-2 Vaccine (Vero 2021 Cell) in Argentine Healthy Population Sponsor: Laboratorio Elea Aged Between 18 and 85 Years Phoenix S.A. 2 doses, day 0 and 21

N=3000 randomised to BIBP vaccine or placebo

Version of 16.10.2020

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Wuhan AND Beijing ChiCTR2000034780 Abu Dhabi, Peru, Phase III trial: The incidence of COVID-19 Rercruiting; High vaccine Morocco and Argentina, Randomized, Double Blind, Parallel cases after two-doses of NCT04510207 Jordan, Bahrain Placebo Controlled, Phase III Clinical vaccination [ Time Frame: Estimated Primary Primary sponsor: Trial to Evaluate the Safety and From14 days after the second Completion: March 16, China National Biotec Phase 3 Protective Efficacy of Inactivated dose to 6 month after the 2021 Group Co.Ltd SARS-CoV-2 Vaccine in Healthy second dose ] Population Aged 18 Years and above Collaborators: G42 Healthcare company; 45000 subjects randomized 1:1:1 to Abu Dhabi Health two different treatment groups or Services Company; placebo Wuhan Institute of Biological Products Co., Ltd; Beijing Institute of Biological Products Co., Ltd

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Chinese Academy of ChiCTR2000032459 China, Sichuan Randomized, double-blinded, and Incidence of adverse Recruiting; High Medical Sciences placebo-controlled phase Ia/IIa reactions/events Estimated primary NCT04412538 clinical trial completion date: Inactivated SARS-CoV-2 Serum conversion rate of September 2020 vaccine; Phase 1/2 N =942 healthy volunteers from 18- neutralizing antibodies and IgG Sponsors and 59 years of age: antibodies in the phase II trial Collaborators: N=192 in the phase I trial, and N=750 at day 14 and 28 Chinese Academy of in the phase II trial. Medical Sciences, West China Second Multiple doses, 2 different schedules University Hospital, Yunnan Center for Disease Control and Prevention Chinese Academy of NCT04470609 China, Sichuan A Randomized, Double-blind, Adverse reactions/events rate [ Enrolling by invitation High Medical Sciences Placebo-controlled, Phase Ib/IIb Trial Time Frame: 7 days and 28 Estimated Primary Phase 1/2 of an Inactivated SARS-CoV-2 Vaccine days after vaccination ] Completion Date: Sponsors and in Healthy People Aged 60 Years November 2020 Collaborators Seroconversion rate of Chinese Academy of N=471 ranodmised to 1 ⩾of 3 doses or Neutralizing antibodies and IgG Medical Sciences placebo. antibodies against SARS-CoV-2 West China Second 1 dose at day 0 and 1 dose at day 28 Phase IIb [ Time Frame: 28 days University Hospital after vaccination ]

Version of 16.10.2020

Yunnan Center for Disease Control and Prevention

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website QazCovid-in® - COVID-19 NCT04530357 Kazakhstan Randomized, Blind, Placebo- Safety and immunogenicity Enrolling by invitation; High inactivated vaccine controlled Phase- i Study and Sponsor: Research Phase 1/2 Randomized, Open Phase Phase-ii Estimated Primary Institute for Biological Study of QAZCOVID-IN®- COVID-19 Completion: December 1, Safety Problems Inactivated Vaccine in Healthy Adult 2020 Volunteers From 18 Years Old and Elder N=244

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website BBV152, Bharat Biotech CTRI/2020/07/02630 India Phase 1, followed by Phase 2 Phase 1: Recruiting; High 0 Randomized, Double-blind, 1. The occurrence of Whole-Virion Inactivated Multicenter Study to Evaluate the immediate adverse events Estimated Primary SARS-CoV-2 Vaccine NCT04471519 Safety, Reactogenicity, Tolerability within two hours of vaccination Completion Date: June and Immunogenicity of the Whole- 2. The occurrence of adverse 2021 Phase 1/2 Virion Inactivated SARS-CoV-2 events within 7 days of Vaccine (BBV152) in Healthy vaccination.3. The occurrence Volunteers. of any adverse events Whole-Virion Inactivated SARS-CoV-2 throughout the study duration 4. The occurrence of serious vaccine (BBV152) with three adverse events (SAEs) formulations, BBV152A, BBV152B and

BBV152C. Dose: 0.5ml, Route of Phase 2: administration: Intramuscular Primary injection, Frequency: Two doses at 1. To evaluate the Day 0 and Day 14 immunogenicity in terms of GMT and four-fold N=1125 seroconversion rate amongst the two selected BBV152 vaccine formulations BBV152, Bharat Biotech CTRI/2020/09/02767 India An Adaptive, Seamless Phase 1, Phase 1 Recruiting; High 4 Followed by a Phase 2, Randomized, 1. The occurrence of Multicenter Study to Evaluate the immediate adverse events Estimated Primary Safety, Reactogenicity, and within two hours of Completion Date: June Immunogenicity of the Whole Virion vaccination. 2021 Inactivated SARS-CoV- 2 Virus 2. The occurrence of adverse Vaccine, BBV152D Administered events within seven days . Intradermally in Healthy Volunteers. 24

Version of 16.10.2020

N=124 3. The occurrence of any adverse events throughout the study duration 4. The occurrence of serious adverse events (SAEs).

Phase 2 1. To evaluate the immunogenicity in terms of four-fold seroconversion rate of SARSCoV- 2 virus neutralizing antibodies across the two dosage strengths of BBV152D.

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Inactivated vaccine, ChiCTR2000038804 Jiangsu, China Evaluation of the safety and Incidence of adverse From2020-10-07To 2022- High Jiangsu immunogenicity of inactivated SARS- reactions/events 04-06 Phase 1 CoV-2 Vaccine(Vero Cells) in healthy Jiangsu Provincial Center population aged 18 years and above: for Disease Control and a randomized, double-blind, placebo Prevention(Public Health parallel-controlled phase I clinical trial Research Institute of N=180 Jiangsu Province)

Beijing Minhai Biotechnology

Version of 16.10.2020 Protein subunit Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website NVX-CoV2373, Novavax NCT04368988 Australia (multiple sites) A 2-Part, phase 1/2, randomized, Safety and immunogenicity Active, not recruiting; High and US observer-blinded study to evaluate measures SARS-CoV-2 Recombinant Phase 1/2 the safety and immunogenicity of a Estimated Primary Spike Protein SARS-CoV-2 recombinant spike Completion Date: Nanoparticle Vaccine protein nanoparticle vaccine (SARS- December 31, 2020 (SARS-CoV-2 rS) CoV-2 rS) with or without MATRIX- M™ Adjuvant in healthy subjects. Sponsor: Novavax N= 1419 healthy subjects aged 18 to 84 years CEPI funding NVX-CoV2373 NCT04533399 South Africa A Phase 2A/B, Randomized, Diagnosis of COVID-19, Recruiting; High Observer-blinded, Placebo-controlled immunogenicity and safety Estimated Primary Sponsor: Novavax Phase 2 Study to Evaluate the Efficacy, measures Completion: November Immunogenicity, and Safety of a 2021 SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS- CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV. N= 2904, 18 to 64 years randomised to vaccine or placebo. 2 doses NVX-CoV2373 2020-004123-16 UK A Phase 3, Randomised, Observer- • FIRST PRIMARY ENDPOINT: Ongoing; High Blinded, Placebo-Controlled Trial to First occurrence of virologically Sponsor: Novavax Phase 3 Evaluate the Efficacy and Safety of a confirmed (by PCR to SARS- Estimated primary SARS-CoV-2 Recombinant Spike CoV-2), symptomatic COVID-19 completion: October 2021 Protein Nanoparticle Vaccine (SARS- with onset at least 7 days after CoV-2 rS) with Matrix-M1 second study vaccination (e.g., Day 28) in serologically N=9,000 negative (to SARS-CoV-2) adult participants at baseline until the endpoint-driven efficacy analysis is triggered by the occurrence of a prespecified number of blinded endpoints.

• SECOND PRIMARY ENDPOINT: First occurrence of virologically confirmed (by PCR to SARS-CoV-2), symptomatic moderate or severe COVID-19 26

Version of 16.10.2020

with onset at least 7 days after second study vaccination (e.g., Day 28) in serologically negative (to SARS-CoV-2) adult participants at baseline until the endpoint-driven efficacy analysis is triggered by the occurrence of a prespecified number of blinded endpoints.

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Adjuvanted recombinant NCT04445194 China, Chongqing A Multi-center, Double-blind, The number of adverse events Recruiting; High protein (RBDDimer), Randomized, Placebo Parallel after intramuscular injection Anhui Zhifei Longcom Phase 1 Controlled, Safety and Tolerability [ Time Frame: Up to one year Estimated primary Biologic Pharmacy Co., Phase I Clinical Trial of Recombinant after the last vaccination ] completion: July 21, 2021 Ltd. Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 Collaborators: The and 59 Years of Age. Second Affiliated Hospital N=50 of Chongqing Medical University Beijing Chao Yang Hospital ChiCTR2000035691, Hu’nan, China A randomized, double-blind, placebo- SARS-CoV-2 neutralizing Recruiting; High Sponsor: Anhui controlled phase I clinical trial for antibody, Zhifeilongkoma NCT04550351 evaluation of the safety and S protein binding antibody Estimated Primary Biopharmaceutical Co., tolerability of recombinant novel (IgG), Completion; October 31, Ltd. Phase 1/2 coronavirus vaccines (CHO cells) in RBD protein binding antibody 2021 Hunan Provincial Center healthy people aged 60 years and (IgG) detection. for Disease Control and above Prevention N=50 NCT04466085 China, Changsha A Randomized, Blinded, Placebo- Neutralizing antibody positive Recruiting; High Sponsor: controlled Trial to Evaluate the conversion rate [ Time Frame: Estimated Primary Anhui Zhifei Longcom Phase 2 Immunogenicity and Safety of a 30 days after inoculation ] Completion Date; Biologic Pharmacy Co., Recombinant New Coronavirus September 15, 2021 Ltd. Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years N=900 randomised to Low dose, high dose or placebo injected as 2 doses or 3 doses

Version of 16.10.2020

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website KBP-COVID-19, Kentucky NCT04473690 Not stated yet A Phase I/II, First-in-human, Solicited Administration site Not yet recruiting; High Bioprocessing, Inc Observer-blinded, Randomized, reactions [ Time Frame: 7 days Phase 1/2 Placebo-controlled, Parallel Group after vaccination ] Estimated primary RBD-based vaccine Study to Evaluate the Safety and Occurrence of Adverse Events completion: March 25, Immunogenicity of KBP-COVID-19 2021 Vaccine in Healthy Seronegative Solicited systemic events [ Adults Aged 18-49 and 50-70. Time Frame: 7 days after Two doses will be tested. vaccination]

N=180

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website S protein NCT04537208 US Immunogenicity and Safety of SARS- Safety and immunogenicity Recruiting; High CoV-2 Recombinant Protein Vaccine Estimated Primary Protein subjunit Phase 1/2 Formulations (With or Without Completion: October 2021 Adjuvant) in Healthy Adults 18 Years Sponsor: of Age and Older Sanofi Pasteur, a Sanofi Company N=440 GlaxoSmithKline

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Native like Trimeric NCT04405908 Australia This is a randomized, double blind, Incidence of solicited adverse Recruiting; High subunit Spike Protein placebo controlled, first-in-human events (AEs) after vaccination [ vaccine, Phase 1 study to assess safety, reactogenicity, Time Frame: 7 days after the Estimated primary Clover/GSK/Dynavax and immunogenicity of SCB-2019 at first or second vaccination. ] completion: October 20, multiple dose levels, administered as Incidence of unsolicited AEs 2020 SCB-2019 with and 2 injections IM in healthy subjects. after vaccination [ Time Frame: without adjuvant (AS03 Each study vaccine dose level will be Day 1 to Day 50 ] or CpG 1018 plus Alum evaluated with and without adjuvant. Immunogenicity(Anti-SCB-2019 adjuvant) Antibody Titers) [ Time Frame: N=150 healthy volunteers stratified Day 1 to Day 184 ] by age, randomised to 1 of 3 doses (3, Geometric mean titer (GMT). 9 or 30 microgram with or without Geometric mean ratio (GMR). Sponsor: Clover adjuvant) Seroconversion rate (SCR). Biopharmaceuticals Inc./GSK/Dynavax Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs) [ Time Frame: Day 1 to Day 184 ]

Version of 16.10.2020

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website COVAX19, Recombinant NCT04453852 Australia, South A Randomised, Controlled, Phase 1 Incidence of Adverse Events [ Recruiting; High spike protein with Australia Study to Evaluate the Safety and Time Frame: 1 weeks post Advax™ adjuvant, Vaxine Phase 1 Immunogenicity of a Candidate immunisation ] Estimated primary Pty Ltd/Medytox Adjuvanted Recombinant Protein completion: July 1, 2021 SARS-COV-2 Vaccine in Healthy Adult COVID19 neutralizing antibody Subjects. titers [ Time Frame: 2 weeks N=40 post second immunisation ]

COVID19 T cell immunogenicity [ Time Frame: 3 weeks post second immunisation ]

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Molecular clamp ACTRN12620000674 Australia A Phase 1 Randomised, Double-Blind, Safety and tolerability Recruiting; High stabilized Spike protein 932p Placebo-Controlled, Dosage- with MF59 adjuvant, Escalation, Single Centre Study To Total serum antibody immune Estimated primary University of https://www.anzctr. Evaluate The Safety And responses completion: July 1, 2021 Queensland/CLS/Seqirus org.au/ Immunogenicity Of An Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Neutralizing antibody (NAb) (MF59 adjuvanted SARS- NCT04495933 Vaccine (COVID-19 vaccine) In immune responses CoV-2 Sclamp vaccine) Healthy Adults Aged 18 To 55 Years Phase 1 Old N=120

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website MVC-COV1901, Medigen NCT04487210 Taiwan A Phase I, Prospective, Open-Labeled Safety of MVC-COV1901 [ Time Not yet recruiting; High Vaccine Biologics Corp. Study to Evaluate the Safety and Frame: Day 1 to 28 days after Phase 1 Immunogenicity of MVC-COV1901 second vaccination ] Estimated primary completion: December 31, N=45. 3 doses will be tested 2021

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Protein subunit, Instituto https://rpcec.sld.cu/ Cuba Phase I / II, randomized, controlled, Serious Adverse Events-SAE. Estimated study High Finlay de Vacunas, Cuba ensayos/RPCEC0000 adaptive, double-blind and Measurement time: daily for completion: January 11, 0332-Sp multicenter study to evaluate the 28 days after each dose. 2021 safety, reactogenicity and Titer of specific anti-RBD IgG Phase 1 immunogenicity of the prophylactic antibodies. Measurement FINLAY-FR-1 anti-SARS-CoV-2 Vaccine time: Baseline and at 14, 28 Candidate in a two-dose schedule. and 56 days 29

Version of 16.10.2020

N=676

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website EpiVacCorona, Federal NCT04527575 Russia Simple, Blind, Placebo-controlled, The proportion of vaccinated Active, not recruiting; High Budgetary Research Randomized Study of the Safety, volunteers with no laboratory Estimated Primary Institution State Phase 1 Reactogenicity and Immunogenicity confirmed symptoms caused Completion: September 1, Research Center of of Vaccine Based on Peptide Antigens by SARS-CoV-2 within 9 2020 Virology and for the Prevention of COVID-19 months post vaccination [ Time Biotechnology "Vector" (EpiVacCorona), in Volunteers Aged Frame: throughout the study, 18-60 Years (I-II Phase) an average of 270 days ] N=100

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website AdimrSC-2f, Adimmune NCT04522089 Taiwan A Randomized, Single Center, Open- The solicited adverse events Recruiting; High label, Dose-finding, Phase I Study to (SoAEs) [ Time Frame: The 7 Protein subunit Phase 1 Evaluate the Safety and days following each Estimated primary Immunogenicity of Pandemic Virus vaccination ], completion: November 20, Vaccine, AdimrSC-2f (SARS-CoV-2), in Incidence of abnormal 2020 Healthy Volunteers laboratory tests results [ Time N=70. 3 doses will be tested Frame: Day 7 after vaccination ]

Version of 16.10.2020 Virus Like Particles Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website RBD-HBsAg VLP ACTRN12620000817 Australia A randomized, observer-blind, Safety and reactogenicity Recruiting; High 943 placebo-controlled, Phase I/II study to Immunogenicity Estimated primary Sponsor: Serum Institute evaluate the safety, reactogenicity completion: March 2021 of India Pvt Ltd Phase 1/2 and immunogenicity of Receptor Binding Domain (RBD) SARS-CoV-2 (COVID-19) Hepatitis B surface antigen (HBsAg) virus like particle (VLP) Vaccine in Healthy Adults

2 doses on day 0 and 28. N= 280, 18-79 years old

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Plant derived VLP, NCT04450004 Canada A Randomized, Partially-Blinded, Safety measures + Neutralizing Active, not recruiting; High Medicago Inc./Université Dose-Ranging Phase 1 Study to Assess antibody [ Time Frame: 21 Laval Phase 1 the Safety, Tolerability, and days ] Estimated primary Immunogenicity of a Recombinant Specific Th1 cell-mediated completion: September Coronavirus-Like Particle COVID 19 immunity (CMI) response [ 12, 2020 Vaccine in Adults 18-55 Years of Age Time Frame: 21 days ] N=180 Specific Th2 cell-mediated immunity (CMI) response [ Time Frame: 21 days ]

Version of 16.10.2020 Other vaccine studies, not yet recruiting Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website DNA vaccine: NCT04334980 Canada, British A Phase 1, Randomized, Observer- Frequency of Adverse Events Not yet recruiting; High bacTRL-Spike Columbia Blind, Placebo-Controlled Trial to Estimated Primary Canada, Nova Scotia Evaluate the Safety, Tolerability and Each participant will remain in Completion Date: Immunogenicity of the bacTRL-Spike the trial for 12-13 month August 31, 2021 Plasmids containing Oral Candidate Vaccine for the synthetic DNA encoding Prevention of COVID-19 in Healthy spike protein from SARS- Adults CoV-2 N=84 Sponsor: Symvivo 3 different doses will be tested Corporation (A Vancouver-based biotech company)

Sponsor: Symvivo Corporation Non-Replicating Viral Early news: USA Phase I estimated to start Q3 2020 TBD Not recruiting; High Vector: Collaboration Estimated study Intranasal vaccine between University completion: Unknown of Alabama at Single dose AdCOVID Birmingham and Altimune Inc.

https://www.drugtar getreview.com/news /59182/biotech-and- academia- collaborate-on- intranasal-covid-19- vaccine- development/ Dendritic Cell Vaccine NCT04386252 US A phase 1/2, randomized, double- Confirm safety [ Time Frame: 6 Not yet recruiting High blinded trial of a vaccine consisting of months ] Sponsor: Aivita autologous dendritic cells loaded with Estimated Primary Biomedical, Inc. antigens from SARS-CoV-2, with or Completion Date: October without GM-CSF, to prevent COVID- 2020 19. Different doses

N = 160 frontline healthcare providers and first responders. Drug: MicroRNA2911 ChiCTR2000031432 China, Jiangsu Phase 1, single center, randomized, Safety and tolerance Not yet recruiting Medium open, dose-increasing, double-blind Sponsor: Nanjing clinical study to evaluate the safety From 2020-04-01 To 2020- University 08-31 32

Version of 16.10.2020

and tolerance of microRNA2911 plasmid in healthy people.

N = 15 healthy adults enrolled in 1-5 dose group to receive 3 times of intravenous infusion for 10 minutes of MicroRNA2911 once a day or every other day.

Other vaccines

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website BCG vaccine NCT04327206 Murdoch Children’s Randomised, multi-center clinical trial TBD Recruiting; High Licensed for tuberculosis Research Institute in to test the use of BCG vaccine against The BRACE trial Australia COVID-19 patients BCG will be assessed for its Estimated primary ability to mitigate the completion: June 30, 2021 Will include 4.170 healthcare workers prevalence and severity of across AU, incl Melbourne Campus’ COVID-19 symptoms. Royal Children’s Hospital

BCG vaccine EudraCT: 2020- Netherlands Randomised placebo controlled Study outcome: “unplanned Active, not recruiting; High University Medical 000919-69 multi-center clinical trial to test the absenteeism” as it will not be Center, Netherlands use of BCG vaccine as protection feasible to visit the sick Estimated Primary NCT04328441 against COVID-19 professionals at home during Completion: March 31, the coronavirus pandemic 2021 Will include 1.000 healthcare workers across 8 Dutch hospitals BCG will be assessed for its ability to mitigate the BCG often cause an injection site prevalence and severity of reaction which will unblind the COVID-19 symptoms. person receiving BCG, but the researchers will remain blinded. BCG vaccine NCT04350931 Egypt Single blind, randomised, placebo Incidence of confirmed COVID- Not yet recruiting; High controlled trial. 19 [ Time Frame: 9 months ] Estimated Primary BCG vaccine is the Estimate the incidence of Completion: October 1, Copenhagen (Danish N=900 healthcare workers will be confirmed COVID-19 among 2020 strain) randomly assigned to receive the healthcare workers in intradermal injection of either BCG isolation hospitals Sponsor: vaccine or normal saline. Ain Shams University Effectiveness of BCG vaccine [ Time Frame: 9 months ] Evaluate the effectiveness of BCG vaccine in protecting the healthcare workers in isolation 33

Version of 16.10.2020

hospitals against the risk of COVID-19 infection by detecting any positive cases among vaccinated healthscare workers

BCG Vaccine NCT04348370 United States: Phase 4, randomized, double-blinded Incidence (measured by Recruiting High Massachusetts and confirmed positive test) of Sponsor: Texas N=700 health care workers SARS-CoV2 infection following Estimated Primary Andrew Dinardo randomized 1:1 to BCG vaccine or BCG vaccination compared to Completion Date: May placebo. placebo [ Time Frame: 2021 Measured daily for up to 6 months ] BCG vaccine NCT04362124 Columbia (multicenter) Phase 3, double-blind, randomized, Primary outcome [ Time Not yet recruiting High clinical trial to evaluate the BCG Frame: From date of Sponsor: vaccination in healthcare workers to randomization to 360 day of Estimated Primary Universidad de Antioquia reduce the severity of SARS-COV-2 the study ] Completion Date: June infection. 2021

N=1000 covid-19 negative health care workers randomized 1:1 to BCG vaccine or placebo. BCG vaccine NCT04369794 Brazil Phase 4, prospective, randomized, 1. Clinical evolution of COVID- Recruiting High of patients already double-blind, multicentre study to 19 [ Time Frame: 45 days of positive for SARS-CoV-2 (BATTLE) evaluate to the impact of previous symptoms onset or diagnosis ] Estimated Study (non-specific effects) (priming effect, from the titer of anti- Completion Date: May BCG interferon-gamma) or current 2. SARS-CoV-2 elimination [ 2022 Sponsor: BCG exposure (boost with Time Frame: 7 days of University of Campinas, intradermal vaccine) on 1) clinical symptoms onset or diagnosis ] Brazil evolution of COVID-19; 2) elimination of SARS-CoV-2 at different times and 3. Seroconversion rate and disease phenotypes; and 3) titration [ Time Frame: 7 days seroconversion rate and titration of symptoms onset or (anti-SARS-CoV-2 IgA, IgM, and IgG). diagnosis

N=1000 randomized to BCG vaccine or placebo. BCG vaccine NCT04373291 Denmark Using BCG vaccine to enhance Number of days of unplanned Not yet recruiting High nonspecific protection of absenteeism for any reason [ Sponsor: 2020‐001888‐90 health care workers during the Time Frame: 6 months ] Estimated Study Bandim Health Project COVID‐19 pandemic. A Completion Date: January BCG-DENMARK- randomised controlled multi‐center 2021 Collaborator: COVID trial. University of Southern Phase 3, multi-center, randomized, Denmark double-blinded placebo-controlled trial using BCG Vaccine to enhance 34

Version of 16.10.2020

non-specific protection of health care workers during the COVID-19 pandemic.

N=1500 hospital personal ≥18 years caring for covid-19 patients randomized 1:1 to BCG vaccine (0,1 mL dose of BCG-Denmark, AJ Vaccines) or placebo (0.1 ml dose sterile 0.9 % NaCl). Bacille Calmette-Guérin NCT04379336 South Africa A phase 3, randomized, double- Incidence of HCWs hospitalized Recruiting High (BCG) blinded, placebo-controlled study to due to COVID-19 per arm [ reduce morbidity and mortality in Time Frame: 52 weeks ] Estimated Primary Sponsor: TASK Applied health care workers exposed to SARS- Completion Date: April 28, Science CoV-2 by enhancing non-specific 2021 immune responses through bacillus calmette-guérin vaccination

N = 500 healthcare workers BCG vaccinaton NCT04384549 France Phase 3, single-blinded, placebo- Incidence of documented Recruiting High controlled, randomized trial on the COVID-19 among health care Sponsor: Assistance Efficacy of Vaccination With Bacillus workers exposed to SARS CoV2 Estimated Primary Publique - Hôpitaux de Calmette and Guérin (BCG) in the and vaccinated with BCG Completion Date: February Paris Prevention of COVID-19 Via the compared to placebo. [Time 11, 2021 Strengthening of Innate Immunity in Frame: during the study period Health Care Workers of 6 months]

N = 1120 healthcare workers in direct contact with Covid-19 patients VPM1002 NCT04439045 Canada A Randomized, Double-blind, Recruiting High Placebo-controlled Phase 3 Study Estimated Primary (Mycobacterium bovis N=3626 Completion: April 1, 2021 rBCGΔureC::hly, live 2-8 × 105 CFU) VPM1002 (a further NCT04387409 Germany Phase 3, double-blind, randomized, Number of days absent from Recruiting High development of the BCG- placebo-controlled multicentre trial work due to respiratory vaccine) VPM1002-DE- to assess the efficacy and safety of disease (with or without Estimated Primary 3.06CoV VPM1002 in reducing healthcare documented SARS-CoV-2 Completion Date: June 30, Sponsor: professionals' absenteeism in the infection) [ Time Frame: From 2021 Vakzine Projekt SARS-CoV-2 pandemic by modulating day 0 to day 240 ] Management GmbH the immune system.

N=1200 health care professionals with high expected exposure to SARSCoV-2 infected patients randomized 1:1 to a single dose (0.1 ml) of either VPM1002 or placebo.

Version of 16.10.2020

BCG vaccination NCT04417335 Netherlands Single blinded, placebo-controlled SARS-CoV-2 related hospital Active, not recruiting; Medium adaptive multi-centre randomized admission [ Time Frame: Estimated primary controlled trial Maximum of 1 year ] completion. May 2021 N=2014 randomised to BCG vaccination or placebo BCG vaccination NCT04414267 Greece A Randomized double blinded Clinical Positive for the respiratory Recruiting; Medium Trial for Enhanced Trained Immune questionnaire consisted of Estimated primary Responses Through Bacillus Calmette- questions concerning the completion: May 25, 2021 Guérin Vaccination to Prevent appearance of symptoms Infections by COVID-19: The possibly, probably and/or ACTIVATE II Trial definitively related to COVID- 19 on visit 3. [ Time Frame: N=900 randomised to BCG or placebo Visit 3 (90 +/- 5 days) ]

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance to website Measles-Mumps-Rubella NCT04357028 Egypt Phase 3, randomized, single-blinded, COVID-19 disease incidence [ Recruiting Medium Vaccine placebo-controlled clinical trial to Time Frame: Time Frame: Estimated primary determine the benefit of measles Measured over the 6 months Completion Date: October Sponsor: Kasr El Aini vaccine in health care professional. following randomization ] 1, 2020 Hospital N = 200 Inactivated ChiCTR2000030016 Guangxi Zhuang, China N=60 with viral negative-transforming Recruiting; Medium mycobacterium vaccine Covid-19 patients randomized to time;30-day cause-specific Sponsor: Guangxi medical http://www.chictr.or mycobacterium vaccine or saline mortality;30-day cause-adverse Dec 12, 2022 university g.cn/showproj.aspx? events;30-day all-cause proj=49799 mortality;co-infections;Time from severe and critical patients to clinical improvement;

Link to WHO’s list of vaccines in preclinical and clinical phases, updated August 25, 2020: https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines